Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Immune Crosstalk Profiling of Non-Hodgkin Lymphoma (NHL) Tumor Immune Microenvironment Identifies Two Clusters Based on T Cell Exhaustion, Correlating with Different Clinical Outcomes

Daniel Medina, Laura Palomo, Víctor Navarro, Cristina García, Juan Camilo Nieto, Júlia Carabia, Carlota Pagès Geli, Pamela Acha, Gemma Pujadas, Carlos Palacio, Laura Gallur, Josep Castellvi, Pau Abrisqueta, Francesc Bosch, Marta Crespo

Blood (2024) 144 (Supplement 1): 6251.

https://doi.org/10.1182/blood-2024-205108

Published: 2024

Journal Articles

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 471.

https://doi.org/10.1182/blood-2024-205809

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

Blood (2024) 144 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2024-201373

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

Single Center Experience Combining Multiple Tools for Genetic Diagnosis of B-Cell Acute Lymphoblastic Leukemia

Gloria Hidalgo-Gomez, Bárbara Tazón-Vega, Carlos Palacio, Silvia Saumell, María Gabarrós-Subirà, Andres Jerez, Adoracion Blanco, Noemí Martínez-Morgado, Víctor Navarro Garces, Laura Murillo, Pablo Velasco, Thais Murciano, Cristina Díaz De Heredia, Francesc Bosch, Gemma Armengol, Margarita Ortega

Blood (2024) 144 (Supplement 1): 2803.

https://doi.org/10.1182/blood-2024-209957

Published: 2024

Journal Articles

Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

Blood (2024) 144 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2024-207871

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Blood (2024) 144 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2024-194488

Published: 2024

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2024-205671

Published: 2024

Journal Articles

Donor Chimerism Monitorization for Relapse Prediction in Ex-Vivo CD34-Selected Allogenic Hematopoietic Stem Cell Transplant

Sergi Camarillas, Gilda Coralia Cetina Castro, Alba Puyuelo, Elisa Roldan, Víctor Navarro Garces, Lorenzo Carita, Ana Perez Gonzalez, Maria Sola, Maria Laura Fox, Félix López-Cadenas, Pilar Verlarde, Guillermo Orti, Antonio Garcia, Anna Martín Carrizosa, Marina Serra, Olga Salamero, David Valcarcel

Blood (2024) 144 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2024-208115

Published: 2024

Journal Articles

Consolidative Allogenic Hematopoietic Cell Transplantation Vs. Watch and Wait Strategy for B-Cell Acute Lymphoblastic Leukemia Patients with Early Loss of B-Cell Aplasia after Chimeric Antigen Receptor T-Cell Therapy

Sergi Camarillas, Anna Alonso-Saladrigues, Agueda Molinos Quintana, Víctor Navarro, Blanca Herrero-Velasco, Mario Sánchez-Salinas, Berta González-Martínez, Ana Africa Martin Lopez, Anna Torrent, Julia Marsal, Juan Luis Reguera, Gloria Iacoboni, Antonio Pérez-Martínez, Susana Rives, Pere Barba

Blood (2024) 144 (Supplement 1): 5898.

https://doi.org/10.1182/blood-2024-205932

Published: 2024

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Blood (2024) 144 (Supplement 1): 666.

https://doi.org/10.1182/blood-2024-194405

Published: 2024

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Autologous Chimeric Antigen Receptor T-Cell Therapy: A Meta-Analysis of 1,154 Patients Included in Clinical Trials

Pere Barba, Victor Navarro Garces, Sergi Camarillas, Cecilia Carpio, Mario Sánchez-Salinas, Samantha Feijoo, Maria Landwehr, Francesc Bosch, Gloria Iacoboni, Guillermo Villacampa

Blood (2024) 144 (Supplement 1): 4186.

https://doi.org/10.1182/blood-2024-205176

Published: 2024

Journal Articles

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

Blood (2024) 144 (16): 1722–1731.

https://doi.org/10.1182/blood.2024023840

Published: 2024

Includes: Supplemental data

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

Blood (2023) 142 (Supplement 1): 4419.

https://doi.org/10.1182/blood-2023-179174

Published: 2023

Journal Articles

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Blood (2023) 142 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2023-179171

Published: 2023

Journal Articles

Multi-Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target

Daniel Medina, Laura Palomo, Víctor Navarro, Oriol Castells, Belén Sánchez, Pau Marc Muñoz Torres, Carlota Pagès Geli, Cristina Hernández, Gemma Pujadas, Alba Cabirta Touzón, Christelle Ferrà, Miguel Alcoceba, María José Terol, Rafael Andreu, Francesc Bosch, Pau Abrisqueta, Marta Crespo

Blood (2023) 142 (Supplement 1): 3254.

https://doi.org/10.1182/blood-2023-185683

Published: 2023

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Gloria Iacoboni, Angel Serna, Victor Navarro Garces, Ana Jimenez Ubieto, Evelyn Valencia, Alberto Lopez Garcia, Itziar Carro, Sergi Camarillas, Josu Iraola, Lucia Medina, Gala Vega, Maria Pozas, Anna Maria Sureda Balari, Raul Cordoba, Miguel Canales, Francesc Bosch, Pere Barba, Pau Abrisqueta Costa

Blood (2023) 142 (Supplement 1): 310.

https://doi.org/10.1182/blood-2023-184883

Published: 2023

NARROW

Immune Crosstalk Profiling of Non-Hodgkin Lymphoma (NHL) Tumor Immune Microenvironment Identifies Two Clusters Based on T Cell Exhaustion, Correlating with Different Clinical Outcomes

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Single Center Experience Combining Multiple Tools for Genetic Diagnosis of B-Cell Acute Lymphoblastic Leukemia

Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Donor Chimerism Monitorization for Relapse Prediction in Ex-Vivo CD34-Selected Allogenic Hematopoietic Stem Cell Transplant

Consolidative Allogenic Hematopoietic Cell Transplantation Vs. Watch and Wait Strategy for B-Cell Acute Lymphoblastic Leukemia Patients with Early Loss of B-Cell Aplasia after Chimeric Antigen Receptor T-Cell Therapy

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Clinical Outcomes of Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Autologous Chimeric Antigen Receptor T-Cell Therapy: A Meta-Analysis of 1,154 Patients Included in Clinical Trials

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Multi-Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only